Trial Profile
A Phase I, Open-label Study to Compare the Pharmacokinetics of Telotristat Ethyl and Its Metabolite in Subjects With Impaired Renal Function to Healthy Subjects With Normal Renal Function After a Single Dose of Telotristat Etiprate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2020
Price :
$35
*
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Pharmacokinetics
- Sponsors Ipsen
- 23 Aug 2018 Status changed from recruiting to completed.
- 26 Feb 2018 New trial record